25 September 2017 - HAS has posted the agenda for the next scheduled TC meeting.

The Transparency Commission will consider the reimbursement of:

• Dolutegravir sodium (Tivicay)
  
• Dinutuximab (Dinutuximab beta Apeiron)
  
• Influenza vaccine (quadrivalent) (Vaxigrip Tetra)
  
• Diphtheria, tetanus, pertussis (acellular, component), hepatitis B, poliomyelitis (inactivated) and Haemophilus influenzae Type b conjugate vaccine (adsorbed) (Vaxelis)
  

Read TC agenda [French]